How does the 9.89% short interest as a percentage of float and 7.24 days to cover impact RGC's volatility?

The 9.89% short interest as a percentage of float and 7.24 days to cover for Regencell Bioscience Holdings Limited (US:RGC) indicate a notable level of short selling activity that can significantly impact the stock's volatility.

Here's a breakdown of how these metrics can influence RGC's price movements:

• Short Interest as a Percentage of Float: This metric represents the proportion of a company's publicly available shares that have been sold short. A higher percentage suggests a significant number of investors are betting against the stock, expecting its price to fall. For RGC, 9.89% of its float is currently shorted. While not exceptionally high compared to some highly-shorted stocks, it's a meaningful figure that can contribute to price sensitivity.
• Days to Cover: This calculates how many days it would take for all short sellers to buy back their borrowed shares, based on the stock's average daily trading volume. RGC's 7.24 days to cover suggests that if short sellers were to rapidly close their positions, it would require over a week of average trading volume to do so.

Impact on Volatility

High short interest and days to cover can lead to increased volatility, particularly in scenarios known as a "short squeeze." A short squeeze occurs when a stock's price begins to rise, forcing short sellers to buy back shares to limit their potential losses. This buying pressure further drives up the price, creating a cascade effect as more short sellers are compelled to cover their positions.

Regencell Bioscience Holdings Limited itself has acknowledged the impact of short selling on its stock price. In an SEC filing from June 30, 2025, the company stated, "We believe a large proportion of our ordinary shares has been and may continue to be traded by short sellers which has put and may continue to put pressure on the supply and demand for our ordinary shares, further influencing volatility in its market price." The company also noted "extreme price and volume fluctuations" that were often "unrelated or disproportionate to the operating performance," citing a significant intra-day price range on June 16, 2025.

Fintel's data for RGC shows a 1-year Volatility of 48.41 and a Beta of 1.95, indicating that the stock has historically experienced higher price fluctuations than the broader market. The combination of these factors suggests that RGC's stock price can be particularly susceptible to sharp movements, both upwards during a short squeeze and downwards if short sellers' convictions are proven correct.

You can find more detailed short interest data, including historical trends and borrow rates for RGC, on Fintel's RGC Short Interest page.

Investigate RGC's short borrow fee rate to understand the cost implications for short sellers holding positions.

The short borrow fee rate is a crucial metric for understanding the cost implications for short sellers and can significantly influence a stock's volatility, especially in conjunction with high short interest.

The short borrow fee, also known as the cost-to-borrow, is the annualized interest rate that a short seller must pay to borrow shares. This fee is paid to the lender of the shares (often institutional investors) and is a continuous expense for as long as the short position is held.

Here's how it impacts short sellers and RGC's volatility:

• Cost of Holding a Short Position: A higher borrow fee directly increases the cost for short sellers. If the fee is substantial, it eats into potential profits and can even lead to losses if the stock price doesn't decline enough to offset the borrowing cost. This pressure can force short sellers to cover their positions sooner than anticipated.
• Indicator of Demand for Shorting: A high borrow fee often indicates strong demand to short a particular stock, suggesting a consensus among some investors that the stock is overvalued or faces significant headwinds. Conversely, it can also signal a scarcity of shares available to borrow.
• Fuel for Short Squeezes: When a stock has high short interest (like RGC's 9.89% of float) and a high borrow fee, the conditions for a short squeeze become more potent. If the stock price starts to rise, short sellers face a double whammy: mounting losses on their positions and increasing costs to maintain those positions. This can trigger a rapid covering of short positions, further driving up the stock price and creating a positive feedback loop. RGC's 7.24 days to cover suggests that if a significant number of short sellers were to cover, it would take more than a week of average trading volume, potentially exacerbating upward price pressure.

While specific real-time borrow fee rates for US:RGC are not directly available in the provided search snippets, Fintel's platform typically provides this data, often updated intraday, showing the start, minimum, maximum, and latest rates for the day. Monitoring this rate for RGC would offer valuable insight into the current sentiment and financial pressure on short sellers. A sudden spike in the borrow fee rate, especially when combined with the existing high short interest and days to cover, could signal an increased risk of a short squeeze.

How does the 9.89% short interest as a percentage of float and 10.54 days to cover impact RGC's volatility?

The updated figure of 10.54 days to cover, alongside the 9.89% short interest as a percentage of float for Regencell Bioscience Holdings Limited (US:RGC), indicates an even more pronounced potential for volatility compared to the previous discussion.

Here's an analysis of how these metrics collectively impact RGC's volatility:

• Elevated Short Interest: The 9.89% short interest as a percentage of float signifies that a substantial portion of RGC's tradable shares are held by investors betting on a price decline. This level of short interest alone suggests a significant bearish sentiment among a segment of the market.
• Increased Days to Cover: The increase from 7.24 to 10.54 days to cover is a critical development. This metric estimates the number of trading days it would take for all short sellers to repurchase their borrowed shares, assuming average daily trading volume. A higher days to cover figure implies that any concerted effort by short sellers to close their positions would exert a more sustained buying pressure on the stock. This extended period of potential buying demand can significantly amplify price movements during a short squeeze scenario.
• Amplified Short Squeeze Potential: The combination of a notable short interest and an extended days to cover creates a fertile ground for a short squeeze. If positive news or a general market upswing causes RGC's stock price to rise, short sellers face increasing losses. To mitigate these losses, they are compelled to buy back shares, which further drives up the price. With 10.54 days to cover, this covering process would take longer, potentially creating a more intense and prolonged upward price spiral as short sellers scramble to exit their positions.
• Company's Acknowledgment of Volatility: Regencell Bioscience Holdings Limited has previously acknowledged the impact of short selling on its stock's volatility. In a June 30, 2025 SEC filing, the company stated its belief that "a large proportion of our ordinary shares has been and may continue to be traded by short sellers which has put and may continue to put pressure on the supply and demand for our ordinary shares, further influencing volatility in its market price." The company also highlighted "extreme price and volume fluctuations" that were often "unrelated or disproportionate to the operating performance," citing significant intra-day price ranges.
• Historical Volatility Data: Fintel's data for RGC shows a 1-year Volatility of 48.41 and a Beta of 1.95, confirming that the stock has historically exhibited higher price fluctuations than the broader market. The current short interest and days to cover figures suggest that this inherent volatility could be exacerbated by short-selling dynamics.

In summary, the 9.89% short interest combined with an elevated 10.54 days to cover indicates a heightened risk of significant price movements, particularly upward volatility if a short squeeze is triggered. This situation suggests that RGC's stock price remains highly sensitive to shifts in sentiment or news events that could force short sellers to cover.

Compare RGC's current short interest and days to cover with those of its direct peers in the biotechnology sector to benchmark its short-selling pressure.

The comparison of Regencell Bioscience Holdings Limited's (US:RGC) short interest and days to cover with its peers in the biotechnology sector provides valuable context for benchmarking its short-selling pressure. While RGC's focus on Traditional Chinese Medicine (TCM) for neurocognitive disorders is niche, examining companies in the broader neurological and mental health biotech space offers a useful comparative perspective.

Here's how RGC's metrics stand against a selection of peers:

• Short Interest as a Percentage of Float:
• RGC: 9.89%
• Harmony Biosciences Holdings, Inc. (HRMY): 9.98%
• Clearmind Medicine Inc. (CMND): 11.48%
• Mind Medicine (MindMed) Inc. (MNMD): 15.75%
• INmune Bio, Inc. (INMB): 32.35%
• AC Immune SA (ACIU): 3.57%
• Psyence Biomedical Ltd. (PBM): 2.37%

RGC's short interest percentage is in the mid-range among these peers. It is notably higher than companies like Psyence Biomedical and AC Immune, suggesting a more significant bearish sentiment or perceived overvaluation by a segment of the market. However, it is lower than MindMed and substantially less than INmune Bio, which faces a considerably higher proportion of its float sold short.

• Days to Cover:
• RGC: 10.54 days
• Clearmind Medicine Inc. (CMND): 11.43 days
• Mind Medicine (MindMed) Inc. (MNMD): 9.90 days
• AC Immune SA (ACIU): 9.87 days
• Harmony Biosciences Holdings, Inc. (HRMY): 7.12 days
• INmune Bio, Inc. (INMB): 2.94 days
• Psyence Biomedical Ltd. (PBM): 0.00 days

RGC's 10.54 days to cover is on the higher end of this peer group, comparable to Clearmind Medicine and higher than MindMed, AC Immune, Harmony Biosciences, and significantly higher than INmune Bio and Psyence Biomedical. A higher days to cover figure indicates that it would take a more extended period for short sellers to repurchase their borrowed shares, implying that any sudden positive catalyst could lead to sustained buying pressure as shorts cover, potentially exacerbating upward price movements. This elevated days to cover, combined with a moderate short interest percentage, suggests that RGC remains susceptible to significant volatility, particularly in the event of a short squeeze.

Fintel's platform provides detailed short interest data, including historical trends and borrow rates for these companies, which can offer further insights into the evolving short-selling dynamics.

Investigate the short borrow fee rates for RGC and its identified peers (MNMD, INMB, HRMY, CMND, ACIU, PBM) to assess the cost pressure on short sellers.

The short borrow fee rate is a critical, dynamic metric that directly impacts the profitability and risk for short sellers, and its comparison across peers offers valuable insights into the relative cost pressure on those betting against a stock. This rate, also known as the cost-to-borrow, is the annualized interest short sellers pay to borrow shares, and it fluctuates based on supply and demand for those lendable shares.

For Regencell Bioscience Holdings Limited (US:RGC) and its peers, these rates can vary significantly:

• AC Immune SA (US:ACIU): Recent data indicates borrow rates for ACIU have been relatively low, hovering around 0.52-0.53% as of August 2025. Such low rates suggest ample supply of shares available for lending and/or low demand from short sellers, reducing the financial burden for those holding short positions.
• Other Peers (MNMD, INMB, HRMY, CMND, PBM) and RGC: While specific real-time borrow fee rates for these US-listed peers and RGC are typically available on Fintel's platform, they were not directly accessible in the public search results without a subscription or specific query. However, the general principle holds: a higher borrow fee increases the carrying cost for short sellers, making it more expensive to maintain their positions.

Implications of Borrow Fee Rates:

• Low Borrow Fees: For stocks with low borrow fees, short sellers face less financial pressure. This can allow them to hold their positions for longer periods, potentially contributing to sustained downward pressure if their bearish thesis is strong.
• High Borrow Fees: Conversely, high borrow fees act as a strong deterrent or a catalyst for short covering. If a stock's borrow rate spikes, it signals either a scarcity of shares available to short or a surge in demand from short sellers, or both. For a stock like RGC, with its 9.89% short interest and 10.54 days to cover, a high borrow fee would significantly amplify the risk of a short squeeze. Short sellers would face increasing daily costs, potentially forcing them to buy back shares to limit losses, which could rapidly drive the stock price higher.

The absence of readily available low borrow rates for a stock with RGC's short interest profile would suggest that short sellers are facing a non-trivial cost to maintain their positions, adding another layer of potential volatility. Monitoring these rates on Fintel's platform for RGC and its specific peers would provide a clearer picture of the financial pressure on short sellers and the potential for short-squeeze events.

Compare RGC's current borrow fee rate against the average and median borrow rates of its identified peers (MNMD, INMB, HRMY, CMND, PBM) over the last three months.

The short borrow fee rate is a critical indicator of the cost burden for short sellers and the overall supply-demand dynamics of a stock's lendable shares. Comparing RGC's borrow fee rate against its peers provides essential context for understanding the relative pressure on short positions and the potential for short squeezes. This rate is the annualized interest short sellers pay to borrow shares, and it fluctuates based on the availability of shares to lend and the demand from short sellers.

Based on available Fintel data snippets for the last three months (July, August, and September 2025), here's a comparison of the borrow fee rates for RGC and its identified peers:

• Psyence Biomedical Ltd. (US:PBM): This stock shows exceptionally high borrow fee rates, ranging from approximately 120% to over 233% during July and early August 2025. Such extreme rates indicate a severe scarcity of shares available for shorting and/or intense demand from short sellers, making it very costly to maintain a short position.
• INmune Bio, Inc. (US:INMB): INmune Bio also exhibits high borrow fees, with rates fluctuating between approximately 30% and 42% in July and early August 2025. These elevated rates suggest significant cost pressure on short sellers, increasing the likelihood of short covering if the stock price moves unfavorably.
• AC Immune SA (US:ACIU): In contrast, AC Immune SA has displayed relatively low and stable borrow fees, consistently around 0.41% in July and early August 2025 for its US listing. This indicates an ample supply of shares available for lending and minimal cost burden for short sellers.
• Regencell Bioscience Holdings Limited (US:RGC), Mind Medicine (MindMed) Inc. (US:MNMD), Harmony Biosciences Holdings, Inc. (US:HRMY), and Clearmind Medicine Inc. (CMND): While Fintel's platform provides short borrow fee rates for these tickers, the specific historical data for the last three months was not fully rendered in the public search snippets. However, the presence of these pages on Fintel confirms that this data is tracked and available.

Implications for RGC:

Given RGC's previously noted 9.89% short interest as a percentage of float and 10.54 days to cover, the borrow fee rate is a crucial missing piece for a complete analysis. If RGC's borrow fee rate is high, similar to PBM or INMB, it would significantly increase the financial risk for short sellers, making the stock highly susceptible to a short squeeze. Conversely, a low borrow fee would suggest that short sellers face less immediate pressure, allowing them to hold their positions for longer.

The divergence in borrow rates among peers highlights that while some biotech companies face substantial costs to short, others do not. This variance underscores the importance of accessing real-time and historical borrow fee data directly from Fintel's platform to accurately gauge the cost pressure on RGC's short sellers and its potential impact on volatility.